{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:03:29Z","timestamp":1784873009873,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging"],"abstract":"<jats:p>Denosumab is a first-line therapy for osteoporosis, yet the rebound increase in bone turnover markers, rapid bone loss, and elevated fracture risk following its discontinuation have become major challenges in clinical management. This review systematically summarizes the potential mechanisms underlying exacerbated bone loss after denosumab withdrawal and the corresponding sequential treatment strategies. Current mechanistic studies have focused on several hypotheses, including the accumulation of osteomorphs and osteoclast precursors, imbalance in the RANKL\/OPG ratio, uncoupling of bone remodeling, and osteocyte-mediated aberrant microdamage repair, which collectively contribute to the burst activation of bone resorption upon treatment cessation. To address this risk, international consensus recommends proactive sequential antiresorptive therapy for patients discontinuing denosumab. For short-term users (\u22642.5\u00a0years), sequential administration of a single dose of zoledronic acid or alendronate can effectively preserve bone mineral density. For long-term users (&amp;gt;2.5\u00a0years), zoledronic acid should be initiated 6\u00a0months after the last dose, accompanied by intensive monitoring based on bone turnover markers and repeated dosing as needed. Additionally, emerging strategies such as early transition to romosozumab or alternating use with bisphosphonates have shown potential. Future studies are required to validate the underlying mechanisms in humans and to optimize sequential treatment regimens through prospective trials, thereby enabling individualized therapy and safe discontinuation.<\/jats:p>","DOI":"10.3389\/fragi.2026.1886424","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:37:09Z","timestamp":1784871429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation"],"prefix":"10.3389","volume":"7","author":[{"given":"Jiancheng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Osteoporosis, Honghui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Osteoporosis, Honghui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Osteoporosis, Honghui Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00223-020-00785-1","article-title":"Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation","volume":"108","author":"Anastasilakis","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-023-01119-7","article-title":"The five-year effect of a single zoledronate infusion on bone mineral density following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"113","author":"Anastasilakis","year":"2023","journal-title":"Calcif. Tissue Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41413-022-00219-8","article-title":"Bone remodeling: an operational process ensuring survival and bone mechanical competence","volume":"10","author":"Bolamperti","year":"2022","journal-title":"Bone Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1359\/jbmr.081210","article-title":"Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue","volume":"24","author":"Cardoso","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41413-024-00362-4","article-title":"Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect","volume":"12","author":"El-Masri","year":"2024","journal-title":"Bone Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e167790","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","volume":"8","author":"Fu","year":"2023","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","article-title":"Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women","volume":"40","author":"Hong","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41413-025-00433-0","article-title":"Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling","volume":"13","author":"Ishikawa","year":"2025","journal-title":"Bone Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fendo.2020.00250","article-title":"Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation","volume":"11","author":"J\u00e4hn-Rickert","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J. Clinical Endocrinol. Metabol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","article-title":"Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study","volume":"80","author":"Khan","year":"2023","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","article-title":"Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition","volume":"39","author":"Kim","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos. Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bonr.2025.101847","article-title":"Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomes","volume":"25","author":"Kumar","year":"2025","journal-title":"Bone Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s40520-025-02991-z","article-title":"Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach","volume":"37","author":"Lamy","year":"2025","journal-title":"Aging Clin. Exp. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","article-title":"Clinical experience with denosumab discontinuation","volume":"36","author":"Laursen","year":"2025","journal-title":"Osteoporos. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2443899","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: a review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40618-025-02542-3","article-title":"Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study","volume":"48","author":"Piasentier","year":"2025","journal-title":"J. Endocrinol. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/jbmr\/zjaf007","article-title":"Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet?","volume":"40","author":"Ramchand","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41419-020-03059-8","article-title":"Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases","volume":"11","author":"Ru","year":"2020","journal-title":"Cell Death Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","article-title":"The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation","volume":"40","author":"Schini","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00198-025-07668-x","article-title":"Follow-on osteoporosis therapy after denosumab discontinuation among medicare beneficiaries","volume":"37","author":"Sendhil","year":"2025","journal-title":"Osteoporos. Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"S\u00f8lling","year":"","journal-title":"Curr. Osteoporos. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"S\u00f8lling","year":"","journal-title":"Osteoporos. Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"B45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"32251","DOI":"10.1073\/pnas.2011504117","article-title":"The mechanoresponse of bone is closely related to the osteocyte lacunocanalicular network architecture","volume":"117","author":"van Tol","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1359\/jbmr.2000.15.1.60","article-title":"Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo","volume":"15","author":"Verborgt","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-020-02308-7","article-title":"CD14(+)CD16(-) monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK","volume":"22","author":"Xue","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/cpt.70088","article-title":"Therapeutic strategies of denosumab sequential therapy: a four-armed randomized controlled trial","volume":"119","author":"Yen","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos. Int."}],"container-title":["Frontiers in Aging"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1886424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:37:09Z","timestamp":1784871429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1886424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":52,"alternative-id":["10.3389\/fragi.2026.1886424"],"URL":"https:\/\/doi.org\/10.3389\/fragi.2026.1886424","relation":{},"ISSN":["2673-6217"],"issn-type":[{"value":"2673-6217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1886424"}}